



FIRST QUARTER 2026 EARNINGS CONFERENCE CALL

APRIL 2026

NASDAQ: PHAT

Today's Agenda

- ▶ **Business Update**
Steven Basta, President & Chief Executive Officer
- ▶ **Financial Update**
Sanjeev Narula, Chief Financial and Business Officer
- ▶ **Closing Remarks**
Steven Basta, President & Chief Executive Officer
- ▶ **Question & Answer**
Steven Basta, President & Chief Executive Officer
Sanjeev Narula, Chief Financial and Business Officer

Safe harbor

This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding: our plans, expectations, strategies, forecasts and goals for commercialization of VOQUEZNA and potential results of our commercialization efforts; our expectations regarding the revenue opportunity and potential market for VOQUEZNA; our guidance and other expectations regarding revenues, operating expenses, and other financial metrics; our expectations with respect to potential profitability, cash flow positivity and our ability, based on our current plans and revenue forecasts, to fund our business and meet outstanding debt obligations without additional equity or debt financing; our expectations regarding regulatory exclusivity and the potential timeline for entry of generic versions of vonoprazan; the potential timelines and impact of approval and launch of other PCABs; our development plans and potential timelines; our business strategy, goals, mission and vision; and our other expectations, forecasts and predictions as to future performance, results and likelihood of success, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “can”, “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential”, “guidance”, or “continue” or the negative of these terms or other similar expressions.

These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risk that: we may not be able to successfully commercialize VOQUEZNA or to achieve results or revenues at the levels we expect; the market opportunity for VOQUEZNA may be significantly smaller than our expectations; market acceptance for VOQUEZNA from healthcare professionals, patients, and payors in the indications for which it is approved may be significantly lower than we anticipate; we may encounter coverage, reimbursement, market access, or other issues in the course of our commercialization efforts that may negatively impact our efforts and results; the unmet need for new treatment options in GERD may not be as high as we anticipate; estimates of the number of patients with the disorders for which VOQUEZNA is approved, now or in the future, and our estimates of potential market size may not be accurate; our decisions as to where to allocate our resources and focus our efforts may not lead to the results we expect; we may not seek, achieve or maintain the patent and regulatory exclusivity we expect or that could be available to us and may encounter generic competition sooner than we anticipate; our results may be negatively impacted by the launch of other competitive products; we may experience adverse impact as the result of our dependence on third parties in connection with commercialization, product manufacturing, research and preclinical and clinical testing; we may be negatively impacted by regulatory developments or other governmental actions in the United States and foreign countries; we may encounter unexpected adverse side effects or inadequate efficacy of VOQUEZNA that may limit or impair market acceptance or impair current or future development or regulatory approvals, or may result in recalls, withdrawals or product liability claims; we may not be able to obtain and maintain intellectual property protection important to our business; if we were to breach our license agreement with Takeda for vonoprazan, Takeda might take action, including termination, that would significantly impair our business; we may encounter issues with our ongoing or planned clinical trials, including slower than expected enrollment that affect timing or chances of success; we may receive negative or mixed results from our ongoing or future clinical trials that impact our business, goals or future opportunities; our operating expenses may be higher than we anticipate, including if we decide to engage in activities not currently in our plan or if we face unexpected, or higher than anticipated, expenses, including as the result of unexpected events such as litigation; depending on our results and activities, we may not achieve profitability or cash flow positivity on the timelines we expect or at all and we may not be able to meet our cash covenant obligations or our other obligations under our term debt or revenue interest financing agreement; in the future, we may not have sufficient cash to fund our operations at the levels we expect or to meet our obligations under certain of our agreements or to enable us to achieve profit from operations; despite our current expectations, we may need to or decide to raise additional capital; we may not be able to raise cash on acceptable terms; and any of the foregoing or other factors may negatively impact our ability to achieve our plans, goals, mission, vision and potential. For additional discussion of these and other risks, see the risk disclosure in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this presentation to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

This presentation also contains estimates and other statistical data made by independent parties and by us. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

This presentation contains non-GAAP operating expense, which excludes stock-based compensation and should be considered only a supplement to, and not a substitute for or superior to, GAAP measures. Refer to slide 12 of this presentation for a reconciliation of the non-GAAP operating expense to GAAP operating expense.

Business Update

Steven Basta, President & Chief Executive Officer

Path to potentially achieving \$1B from GI writers

**Current
GI
Focus**

- ▶ GI oriented realignment
- ▶ High GI call frequency
- ▶ Depth of GI writing



$$\sim 20\text{M PPI TRx} \times 20\text{-}30\% \text{ potential market share} = \sim 4\text{-}6\text{M VOQUEZNA TRx}$$

Annual PPI scripts written by GIs & GI APPs¹

Positive signal: ~20% average share among top 300 VOQUEZNA GI writers²

Path to ~\$1B/yr revenue potential in GI

Future PCP Plans



Patients cycle back to primary care



Potential primary care sales force expansion



Synergistic & efficient DTC advertising

¹ IQVIA trailing 12 months as of October 2025 (including Advanced Practice Providers (APPs) = nurse practitioners and physician assistants).
² Average of individual shares of writing demonstrated by the top 300 GI VOQUEZNA writers during Q1 2026 (based on VOQUEZNA + PPI TRx).

Strong NBRx market share among our top GI writers

Q1 2026



VOQUEZNA NBRx Market Share¹ PPI NBRx Market Share¹

Q1 2026 key financial results



\$58.3M

net revenues



\$56.2M

operating expenses¹



~\$15M

net cash usage

~\$181M

cash and cash equivalents
(as of 3/31/26)

Covered TRx grew ~91% from Q1 2025 to Q1 2026


~268,000

Total Prescriptions Filled in Q1 2026

Covered Prescriptions¹




Cash-Pay Prescriptions¹



NBRx + persistence = future TRx growth potential

Covered NBRx



**~11% growth from
Q4 2025 to Q1 2026**

in covered new-to-brand prescriptions¹

Patient Persistence



12-months

**~6 bottles worth of
VOQUEZNA dispensed**

on average over a 12-month period²

¹ IQVIA + BlinkRx as of 3/31/26.

² IQVIA APLD + BlinkRx claims for a cohort of patients beginning GERD therapy in 2024 and tracked for 12 months.



VOQUEZNA[®]
(vonoprazan) tablets ^{10mg}
^{20mg}


Financial Update

Sanjeev Narula, Chief Financial and Business Officer


Revenues doubled from Q1 2025 to Q1 2026

~\$181M cash and cash equivalents
(as of 3/31/26)

Net Revenue



Operating Expenses¹



2026 financial guidance

Net Revenues

\$320M
to
\$345M

GTN Discount

55%
to
59%

Operating Expenses¹

\$235M
to
\$255M

Path to Profitability

- 2026:** We anticipate we will achieve operating profitability by Q3 and in total for the full year 2026, excluding stock-based compensation
- 2027:** We believe we will achieve cash flow positivity in 2027



VOQUEZNA[®]
(vonoprazan) tablets ^{10mg}
^{20mg}

Closing Remarks

Steven Basta, President & Chief Executive Officer

Question & Answer

Steven Basta, President & Chief Executive Officer
Sanjeev Narula, Chief Financial and Business Officer